Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CervoMed Inc.CRVO · Entity 7338 | Director · 10% owner | June 11, 2026 | June 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CervoMed Inc.
Report date June 11, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Trusts | 1,795,865 |
Reported balance
After 2026-06-11 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-06-11 · Purchase · Acquired 955,414 · Balance 1,795,865 F1: On June 11, 2026, the Issuer completed a private placement (the "Private Placement") pursuant to a securities purchase agreement, dated June 9, 2026 (the "Purchase Agreement"), with the Joshua S. Boger 2021 Trust DTD 12/09/2021, of which the Reporting Person serves as the sole trustee (the "JSB 2021 Trust"), and certain accredited investors named therein. Pursuant to the Purchase Agreement, the JSB 2021 Trust purchased an aggregate of 955,414 units (the "Units"), each Unit comprised of (i) one share of the Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) one Series B warrant to purchase one share of Common Stock or a pre-funded warrant to purchase one share of Common Stock (each, a "Series B Warrant"), and (iii) one Series C warrant to purchase one share of Common Stock or a pre-funded warrant to purchase one share of Common Stock (each, a "Series C Warrant") for a purchase price of $3.14 per Unit. F2: After giving effect to all transactions described herein, consists of (i) 1,600,117 shares of the Issuer's common stock held by the JSB 2021 Trust and (ii) 195,748 shares of the Issuer's common stock held by The Amy S. Boger 2021 Trust (the "ASB 2021 Trust"). The Reporting Person serves as the sole trustee of each of the JSB 2021 Trust and the ASB 2021 Trust. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. |
| Series B WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $3.32 · Expires 2031-06-11 | IndirectBy Trust | 955,414 |
Reported balance
After 2026-06-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-11 · Purchase · Acquired 955,414 · Balance 955,414 F3: The Series B Warrants have an exercise price equal to $3.32 per share of Common Stock or $3.319 per pre-funded warrant, are exercisable immediately, and will expire five years from the issuance date of the Series B Warrant. F5: Under the terms of the Series B Warrants and the Series C Warrants, the Issuer may not effect the exercise of any portion thereof, and the JSB 2021 Trust will not have the right to exercise any portion thereof, which, upon giving effect to such exercise, would cause the JSB 2021 Trust (together with its affiliates) to own more than 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. To the extent that exercise of the Series B Warrants or Series C Warrants will result in the JSB 2021 Trust (together with its affiliates) beneficially owning shares of Common Stock above such ownership limitations, the JSB 2021 Trust may exercise its Series B Warrants or Series C Warrants for pre-funded warrants to purchase shares of Common Stock, which pre-funded warrants will include a substantially similar maximum ownership limitation. F1: On June 11, 2026, the Issuer completed a private placement (the "Private Placement") pursuant to a securities purchase agreement, dated June 9, 2026 (the "Purchase Agreement"), with the Joshua S. Boger 2021 Trust DTD 12/09/2021, of which the Reporting Person serves as the sole trustee (the "JSB 2021 Trust"), and certain accredited investors named therein. Pursuant to the Purchase Agreement, the JSB 2021 Trust purchased an aggregate of 955,414 units (the "Units"), each Unit comprised of (i) one share of the Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) one Series B warrant to purchase one share of Common Stock or a pre-funded warrant to purchase one share of Common Stock (each, a "Series B Warrant"), and (iii) one Series C warrant to purchase one share of Common Stock or a pre-funded warrant to purchase one share of Common Stock (each, a "Series C Warrant") for a purchase price of $3.14 per Unit. F6: The Series B Warrants and Series C Warrants are owned by the JSB 2021 Trust. |
| Series C WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $3.14 · Expires 2027-06-11 | IndirectBy Trust | 955,414 |
Reported balance
After 2026-06-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-11 · Purchase · Acquired 955,414 · Balance 955,414 F4: The Series C Warrants have an exercise price equal to $3.14 per share of Common Stock or $3.139 per pre-funded warrant, are exercisable immediately, and will expire one year from the issuance date of the Series C Warrant. F5: Under the terms of the Series B Warrants and the Series C Warrants, the Issuer may not effect the exercise of any portion thereof, and the JSB 2021 Trust will not have the right to exercise any portion thereof, which, upon giving effect to such exercise, would cause the JSB 2021 Trust (together with its affiliates) to own more than 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. To the extent that exercise of the Series B Warrants or Series C Warrants will result in the JSB 2021 Trust (together with its affiliates) beneficially owning shares of Common Stock above such ownership limitations, the JSB 2021 Trust may exercise its Series B Warrants or Series C Warrants for pre-funded warrants to purchase shares of Common Stock, which pre-funded warrants will include a substantially similar maximum ownership limitation. F1: On June 11, 2026, the Issuer completed a private placement (the "Private Placement") pursuant to a securities purchase agreement, dated June 9, 2026 (the "Purchase Agreement"), with the Joshua S. Boger 2021 Trust DTD 12/09/2021, of which the Reporting Person serves as the sole trustee (the "JSB 2021 Trust"), and certain accredited investors named therein. Pursuant to the Purchase Agreement, the JSB 2021 Trust purchased an aggregate of 955,414 units (the "Units"), each Unit comprised of (i) one share of the Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) one Series B warrant to purchase one share of Common Stock or a pre-funded warrant to purchase one share of Common Stock (each, a "Series B Warrant"), and (iii) one Series C warrant to purchase one share of Common Stock or a pre-funded warrant to purchase one share of Common Stock (each, a "Series C Warrant") for a purchase price of $3.14 per Unit. F6: The Series B Warrants and Series C Warrants are owned by the JSB 2021 Trust. |
| Common StockSEC Table I · non-derivative | Direct | 216,817 |
Reported balance
Holding disclosure · report date 2026-06-11 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 216,817 |
Filing footnotes · ownership attribution and instrument terms
F1: On June 11, 2026, the Issuer completed a private placement (the "Private Placement") pursuant to a securities purchase agreement, dated June 9, 2026 (the "Purchase Agreement"), with the Joshua S. Boger 2021 Trust DTD 12/09/2021, of which the Reporting Person serves as the sole trustee (the "JSB 2021 Trust"), and certain accredited investors named therein. Pursuant to the Purchase Agreement, the JSB 2021 Trust purchased an aggregate of 955,414 units (the "Units"), each Unit comprised of (i) one share of the Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) one Series B warrant to purchase one share of Common Stock or a pre-funded warrant to purchase one share of Common Stock (each, a "Series B Warrant"), and (iii) one Series C warrant to purchase one share of Common Stock or a pre-funded warrant to purchase one share of Common Stock (each, a "Series C Warrant") for a purchase price of $3.14 per Unit.
F2: After giving effect to all transactions described herein, consists of (i) 1,600,117 shares of the Issuer's common stock held by the JSB 2021 Trust and (ii) 195,748 shares of the Issuer's common stock held by The Amy S. Boger 2021 Trust (the "ASB 2021 Trust"). The Reporting Person serves as the sole trustee of each of the JSB 2021 Trust and the ASB 2021 Trust. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
F3: The Series B Warrants have an exercise price equal to $3.32 per share of Common Stock or $3.319 per pre-funded warrant, are exercisable immediately, and will expire five years from the issuance date of the Series B Warrant.
F4: The Series C Warrants have an exercise price equal to $3.14 per share of Common Stock or $3.139 per pre-funded warrant, are exercisable immediately, and will expire one year from the issuance date of the Series C Warrant.
F5: Under the terms of the Series B Warrants and the Series C Warrants, the Issuer may not effect the exercise of any portion thereof, and the JSB 2021 Trust will not have the right to exercise any portion thereof, which, upon giving effect to such exercise, would cause the JSB 2021 Trust (together with its affiliates) to own more than 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. To the extent that exercise of the Series B Warrants or Series C Warrants will result in the JSB 2021 Trust (together with its affiliates) beneficially owning shares of Common Stock above such ownership limitations, the JSB 2021 Trust may exercise its Series B Warrants or Series C Warrants for pre-funded warrants to purchase shares of Common Stock, which pre-funded warrants will include a substantially similar maximum ownership limitation.
F6: The Series B Warrants and Series C Warrants are owned by the JSB 2021 Trust.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
VERTEX PHARMACEUTICALS INC / MA
Report date June 08, 2017 · Filed June 09, 2017
Section 16 reporting ended · disclosed 2017-06-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 284,088 |
Reported balance
After 2017-06-08 transaction · row 1
1 source rowRow 1 · 2017-06-08 · Exercise / conversion · Acquired 2,941 · Balance 284,088 F1: Each deferred stock unit represents one share of common stock and converted into common stock upon the termination of Dr. Boger's service on our board of directors on 06/08/2017. |
| Deferred Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2017-06-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-06-08 · Exercise / conversion · Disposed 2,941 · Balance 0 F1: Each deferred stock unit represents one share of common stock and converted into common stock upon the termination of Dr. Boger's service on our board of directors on 06/08/2017. |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 13,286 |
Reported balance
Holding disclosure · report date 2017-06-08 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 13,286 |
| Common StockSEC Table I · non-derivative | IndirectCommon Stock Held In Trust | 64,525 |
Reported balance
Holding disclosure · report date 2017-06-08 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 64,525 |
Filing footnotes · ownership attribution and instrument terms
F1: Each deferred stock unit represents one share of common stock and converted into common stock upon the termination of Dr. Boger's service on our board of directors on 06/08/2017.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 21, 2016 Filed Sep 23, 2016 20:50 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,900 | $91.82 | $174,458.00 |
DisclosureSEC source: 0001209191-16-142628 · doc4.xml · nonDerivative · entry 4 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,425 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $91.82 (range $91.27 to $92.21). Read SEC document |
| September 21, 2016 Filed Sep 23, 2016 20:50 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,500 | $90.77 | $226,925.00 |
DisclosureSEC source: 0001209191-16-142628 · doc4.xml · nonDerivative · entry 3 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,325 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $90.77 (range $90.25 to $91.23). Read SEC document |
| September 21, 2016 Filed Sep 23, 2016 20:50 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,900 | $89.73 | $170,487.00 |
DisclosureSEC source: 0001209191-16-142628 · doc4.xml · nonDerivative · entry 2 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,825 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $89.73 (range $89.21 to $90.20). Read SEC document |
| September 21, 2016 Filed Sep 23, 2016 20:50 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 6,500 | $36.30 | $235,950.00 |
DisclosureSEC source: 0001209191-16-142628 · doc4.xml · nonDerivative · entry 1 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,725 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 14, 2016 Filed Sep 16, 2016 19:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,500 | $0.00 Strike: $36.30 | $0.00 |
DisclosureSEC source: 0001209191-16-141765 · doc4.xml · derivative · entry 9 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,000 Underlying: Common Stock · 6,500 shares Expires 2017-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Fully vested. Read SEC document |
| September 14, 2016 Filed Sep 16, 2016 19:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,700 | $97.17 | $165,189.00 |
DisclosureSEC source: 0001209191-16-141765 · doc4.xml · nonDerivative · entry 6 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,225 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $97.17 (range $96.83 to $97.71). Read SEC document |
| September 14, 2016 Filed Sep 16, 2016 19:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 700 | $96.20 | $67,340.00 |
DisclosureSEC source: 0001209191-16-141765 · doc4.xml · nonDerivative · entry 5 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,925 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $96.20 (range $95.78 to $96.72). Read SEC document |
| September 14, 2016 Filed Sep 16, 2016 19:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 200 | $90.27 | $18,054.00 |
DisclosureSEC source: 0001209191-16-141765 · doc4.xml · nonDerivative · entry 4 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,625 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $90.27 (range $90.26 to $90.28). Read SEC document |
| September 14, 2016 Filed Sep 16, 2016 19:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,500 | $89.80 | $314,300.00 |
DisclosureSEC source: 0001209191-16-141765 · doc4.xml · nonDerivative · entry 3 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,825 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $89.80 (range $89.26 to $90.20). Read SEC document |
| September 14, 2016 Filed Sep 16, 2016 19:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 400 | $88.76 | $35,504.00 |
DisclosureSEC source: 0001209191-16-141765 · doc4.xml · nonDerivative · entry 2 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,325 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $88.76 (range $88.22 to $88.99). Read SEC document |
| September 14, 2016 Filed Sep 16, 2016 19:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 6,500 | $36.30 | $235,950.00 |
DisclosureSEC source: 0001209191-16-141765 · doc4.xml · nonDerivative · entry 1 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,725 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 07, 2016 Filed Sep 9, 2016 16:45 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,500 | $0.00 Strike: $36.30 | $0.00 |
DisclosureSEC source: 0001209191-16-140710 · doc4.xml · derivative · entry 6 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,500 Underlying: Common Stock · 6,500 shares Expires 2017-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. Read SEC document |
| September 07, 2016 Filed Sep 9, 2016 16:45 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 500 | $96.27 | $48,135.00 |
DisclosureSEC source: 0001209191-16-140710 · doc4.xml · nonDerivative · entry 3 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,225 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $96.27 (range $96.17 to $96.54). Read SEC document |
| September 07, 2016 Filed Sep 9, 2016 16:45 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 6,000 | $95.61 | $573,660.00 |
DisclosureSEC source: 0001209191-16-140710 · doc4.xml · nonDerivative · entry 2 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,725 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $95.61 (range $95.17 to $96.16). Read SEC document |
| September 07, 2016 Filed Sep 9, 2016 16:45 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 6,500 | $36.30 | $235,950.00 |
DisclosureSEC source: 0001209191-16-140710 · doc4.xml · nonDerivative · entry 1 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,725 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2016 Filed Sep 2, 2016 16:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,500 | $0.00 Strike: $36.30 | $0.00 |
DisclosureSEC source: 0001209191-16-139637 · doc4.xml · derivative · entry 6 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 6,500 shares Expires 2017-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. Read SEC document |
| August 31, 2016 Filed Sep 2, 2016 16:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 800 | $95.28 | $76,224.00 |
DisclosureSEC source: 0001209191-16-139637 · doc4.xml · nonDerivative · entry 3 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,225 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $95.28 (range $95.05 to $95.52). Read SEC document |
| August 31, 2016 Filed Sep 2, 2016 16:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 5,700 | $94.53 | $538,821.00 |
DisclosureSEC source: 0001209191-16-139637 · doc4.xml · nonDerivative · entry 2 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,025 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $94.53 (range $94.04 to $94.96). F3 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| August 31, 2016 Filed Sep 2, 2016 16:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 6,500 | $36.30 | $235,950.00 |
DisclosureSEC source: 0001209191-16-139637 · doc4.xml · nonDerivative · entry 1 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,725 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 24, 2016 Filed Aug 26, 2016 17:51 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,500 | $0.00 Strike: $36.30 | $0.00 |
DisclosureSEC source: 0001209191-16-138764 · doc4.xml · derivative · entry 10 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,500 Underlying: Common Stock · 6,500 shares Expires 2017-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Fully vested. Read SEC document |
| August 24, 2016 Filed Aug 26, 2016 17:51 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 900 | $101.60 | $91,440.00 |
DisclosureSEC source: 0001209191-16-138764 · doc4.xml · nonDerivative · entry 9 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Common Stock Held In Trust Disclosed balance after: 78,200 F1 · kind: Transaction made pursuant to the holder's company approved trading plan under Rule 10b5-1. F2 · price: The holder undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $101.60 (range $101.25 to $102.00). Read SEC document |
| August 24, 2016 Filed Aug 26, 2016 17:51 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $100.02 | $10,002.00 |
DisclosureSEC source: 0001209191-16-138764 · doc4.xml · nonDerivative · entry 8 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Common Stock Held In Trust Disclosed balance after: 79,100 F1 · kind: Transaction made pursuant to the holder's company approved trading plan under Rule 10b5-1. Read SEC document |
| August 24, 2016 Filed Aug 26, 2016 17:51 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,800 | $101.83 | $285,124.00 |
DisclosureSEC source: 0001209191-16-138764 · doc4.xml · nonDerivative · entry 6 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,225 F1 · kind: Transaction made pursuant to the holder's company approved trading plan under Rule 10b5-1. F2 · price: The holder undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $101.83 (range $101.63 to $102.45). Read SEC document |
| August 24, 2016 Filed Aug 26, 2016 17:51 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,500 | $101.21 | $151,815.00 |
DisclosureSEC source: 0001209191-16-138764 · doc4.xml · nonDerivative · entry 5 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,025 F1 · kind: Transaction made pursuant to the holder's company approved trading plan under Rule 10b5-1. F2 · price: The holder undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $101.21 (range $100.63 to $101.60). Read SEC document |
| August 24, 2016 Filed Aug 26, 2016 17:51 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $99.50 | $9,950.00 |
DisclosureSEC source: 0001209191-16-138764 · doc4.xml · nonDerivative · entry 4 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,525 F1 · kind: Transaction made pursuant to the holder's company approved trading plan under Rule 10b5-1. Read SEC document |
| August 24, 2016 Filed Aug 26, 2016 17:51 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,000 | $98.74 | $98,740.00 |
DisclosureSEC source: 0001209191-16-138764 · doc4.xml · nonDerivative · entry 3 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,625 F1 · kind: Transaction made pursuant to the holder's company approved trading plan under Rule 10b5-1. F2 · price: The holder undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $98.74 (range $98.37 to $99.19). Read SEC document |
| August 24, 2016 Filed Aug 26, 2016 17:51 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,100 | $96.73 | $106,403.00 |
DisclosureSEC source: 0001209191-16-138764 · doc4.xml · nonDerivative · entry 2 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,625 F1 · kind: Transaction made pursuant to the holder's company approved trading plan under Rule 10b5-1. F2 · price: The holder undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $96.73 (range $96.40 to $97.37). Read SEC document |
| August 24, 2016 Filed Aug 26, 2016 17:51 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 6,500 | $36.30 | $235,950.00 |
DisclosureSEC source: 0001209191-16-138764 · doc4.xml · nonDerivative · entry 1 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,725 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 22, 2016 Filed Aug 24, 2016 16:32 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $101.39 | $10,139.00 |
DisclosureSEC source: 0001209191-16-138429 · doc4.xml · nonDerivative · entry 4 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Common Stock Held In Trust Disclosed balance after: 79,200 F1 · kind: Transaction made pursuant to the holder's company approved trading plan under Rule 10b5-1. Read SEC document |
| August 22, 2016 Filed Aug 24, 2016 16:32 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,000 | $100.73 | $100,730.00 |
DisclosureSEC source: 0001209191-16-138429 · doc4.xml · nonDerivative · entry 3 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Common Stock Held In Trust Disclosed balance after: 79,300 F1 · kind: Transaction made pursuant to the holder's company approved trading plan under Rule 10b5-1. F2 · price: The holder undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $100.73 (range $100.16 to $101.08). Read SEC document |
| August 17, 2016 Filed Aug 18, 2016 20:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,500 | $0.00 Strike: $36.30 | $0.00 |
DisclosureSEC source: 0001209191-16-137770 · doc4.xml · derivative · entry 6 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,000 Underlying: Common Stock · 6,500 shares Expires 2017-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully vested. Read SEC document |
| August 17, 2016 Filed Aug 18, 2016 20:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 400 | $100.03 | $40,012.00 |
DisclosureSEC source: 0001209191-16-137770 · doc4.xml · nonDerivative · entry 5 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Common Stock Held In Trust Disclosed balance after: 80,300 F1 · kind: Transaction made pursuant to the holder's company approved trading plan under Rule 10b5-1. F2 · price: The holder undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $100.03 (range $100.00 to $100.08). Read SEC document |
| August 17, 2016 Filed Aug 18, 2016 20:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,500 | $99.99 | $249,975.00 |
DisclosureSEC source: 0001209191-16-137770 · doc4.xml · nonDerivative · entry 3 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,225 F1 · kind: Transaction made pursuant to the holder's company approved trading plan under Rule 10b5-1. F2 · price: The holder undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $99.99 (range $99.91 to $100.12). Read SEC document |
| August 17, 2016 Filed Aug 18, 2016 20:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,000 | $99.36 | $397,440.00 |
DisclosureSEC source: 0001209191-16-137770 · doc4.xml · nonDerivative · entry 2 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,725 F1 · kind: Transaction made pursuant to the holder's company approved trading plan under Rule 10b5-1. F2 · price: The holder undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $99.36 (range $98.87 to $99.84). Read SEC document |
| August 17, 2016 Filed Aug 18, 2016 20:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 6,500 | $36.30 | $235,950.00 |
DisclosureSEC source: 0001209191-16-137770 · doc4.xml · nonDerivative · entry 1 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,725 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 11, 2016 Filed Aug 12, 2016 14:55 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 900 | $100.19 | $90,171.00 |
DisclosureSEC source: 0001209191-16-136716 · doc4.xml · nonDerivative · entry 3 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Common Stock Held In Trust Disclosed balance after: 80,700 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: The holder undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $100.19 (range $100.07 to $100.25). Read SEC document |
| August 10, 2016 Filed Aug 11, 2016 20:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,500 | $0.00 Strike: $36.30 | $0.00 |
DisclosureSEC source: 0001209191-16-136549 · doc4.xml · derivative · entry 7 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,500 Underlying: Common Stock · 6,500 shares Expires 2017-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully vested. Read SEC document |
| August 10, 2016 Filed Aug 11, 2016 20:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 200 | $101.34 | $20,268.00 |
DisclosureSEC source: 0001209191-16-136549 · doc4.xml · nonDerivative · entry 6 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Common Stock Held In Trust Disclosed balance after: 81,600 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. Read SEC document |
| August 10, 2016 Filed Aug 11, 2016 20:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 400 | $100.38 | $40,152.00 |
DisclosureSEC source: 0001209191-16-136549 · doc4.xml · nonDerivative · entry 5 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Common Stock Held In Trust Disclosed balance after: 81,800 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: The holder undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $100.38 (range $100.29 to $100.60). Read SEC document |
| August 10, 2016 Filed Aug 11, 2016 20:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,600 | $100.93 | $161,488.00 |
DisclosureSEC source: 0001209191-16-136549 · doc4.xml · nonDerivative · entry 3 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,225 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: The holder undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $100.93 (range $100.59 to $101.38). Read SEC document |
| August 10, 2016 Filed Aug 11, 2016 20:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,900 | $99.96 | $489,804.00 |
DisclosureSEC source: 0001209191-16-136549 · doc4.xml · nonDerivative · entry 2 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,825 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: The holder undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $99.96 (range $99.55 to $100.35). Read SEC document |
| August 10, 2016 Filed Aug 11, 2016 20:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 6,500 | $36.30 | $235,950.00 |
DisclosureSEC source: 0001209191-16-136549 · doc4.xml · nonDerivative · entry 1 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,725 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2016 Filed Aug 5, 2016 17:01 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,500 | $0.00 Strike: $36.30 | $0.00 |
DisclosureSEC source: 0001209191-16-135653 · doc4.xml · derivative · entry 7 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,000 Underlying: Common Stock · 6,500 shares Expires 2017-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully vested. Read SEC document |
| August 03, 2016 Filed Aug 5, 2016 17:01 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 10,000 | $101.17 | $1,011,700.00 |
DisclosureSEC source: 0001209191-16-135653 · doc4.xml · nonDerivative · entry 6 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Common Stock Held In Trust Disclosed balance after: 82,200 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: The holder undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $101.17 (range $101.00 to $101.50). Read SEC document |
| August 03, 2016 Filed Aug 5, 2016 17:01 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 30,500 | $100.55 | $3,066,775.00 |
DisclosureSEC source: 0001209191-16-135653 · doc4.xml · nonDerivative · entry 5 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Common Stock Held In Trust Disclosed balance after: 92,200 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: The holder undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $100.55 (range $100.00 to $100.99). Read SEC document |
| August 03, 2016 Filed Aug 5, 2016 17:01 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,200 | $100.74 | $322,368.00 |
DisclosureSEC source: 0001209191-16-135653 · doc4.xml · nonDerivative · entry 3 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,225 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: The holder undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $100.74 (range $100.47 to $101.37). Read SEC document |
| August 03, 2016 Filed Aug 5, 2016 17:01 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,300 | $100.09 | $330,297.00 |
DisclosureSEC source: 0001209191-16-135653 · doc4.xml · nonDerivative · entry 2 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,425 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: The holder undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $100.09 (range $99.44 to $100.43). Read SEC document |
| August 03, 2016 Filed Aug 5, 2016 17:01 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 6,500 | $36.30 | $235,950.00 |
DisclosureSEC source: 0001209191-16-135653 · doc4.xml · nonDerivative · entry 1 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,725 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 27, 2016 Filed Jul 29, 2016 19:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,500 | $0.00 Strike: $36.30 | $0.00 |
DisclosureSEC source: 0001209191-16-134422 · doc4.xml · derivative · entry 6 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,500 Underlying: Common Stock · 6,500 shares Expires 2017-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. Read SEC document |
| July 27, 2016 Filed Jul 29, 2016 19:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 400 | $96.55 | $38,620.00 |
DisclosureSEC source: 0001209191-16-134422 · doc4.xml · nonDerivative · entry 3 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,225 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $96.55 (range $96.43 to $96.76). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.